Trial Profile
Pivotal phase I pharmacokinetic study of bevacizumab biosimilar (ONS-1045) compared with Avastin in volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer; Lung cancer
- Focus First in man; Pharmacokinetics; Registrational
- Sponsors Outlook Therapeutics
- 05 Oct 2015 Primary endpoint (Area under the time-concentration curve from first time point extrapolated to infinity) has been met, according to Oncobiologics media release.
- 20 Apr 2015 New trial record
- 15 Apr 2015 Dosing in this pivotal study has been completed, according to an Oncobiologics media release.